The results, published in Pediatrics, demonstrate a significant improvement in SCD care for pediatric patients in BMC’s emergency department and could serve as a model for other hospitals across the country.
Sickle cell disease affects approximately 100,000 Americans and can cause numerous complications, including severe pain and increased risk for infection, stroke and death. One complication, called a Vaso-occlusive episode (VOE), causes extreme, debilitating pain and is one of the most common reasons that patients with SCD go to the emergency department and/or are hospitalized. In Boston, BMC cares for approximately 50 percent of the pediatric patients with SCD – close to 200 patients.
The National Heart, Lung, and Blood Institute recommends that pediatric patients with SCD who are experiencing a VOE be triaged and treated as quickly as possible in the emergency department. However, previous national studies have indicated that these patients often wait, on average, between 65 and 90 minutes for the first dose of pain medication.
“When a child with sickle cell disease comes to the emergency room with pain from a VOE, they likely have been in tremendous pain for hours,” said Patricia Kavanagh, MD, MSc, pediatrician at BMC and assistant professor of pediatrics at Boston University School of Medicine (BUSM). “The goal of this initiative was to treat the pain episode as quickly and aggressively as possible so that these children could return to their usual activities, including school and time with family and friends.”
From September 2010 to April 2014, a multidisciplinary team at BMC worked in the pediatric emergency department to change how these patients were triaged and treated. The four interventions they focused on to improve care included: the development of a standardized time-specific protocol that guided care when the patient is in the emergency department; using intranasal fentanyl – a pain medication taken through the nose – as a first-line pain medication since placing intravenous lines (IVs) can be hard in children with SCD; using an online “calculator” to quickly determine appropriate pain medication doses in line with what is used nationally for children in the emergency department; and providing education to both emergency providers and families on this work.
The results of the four initiatives included a reduction in the average time from triage to the first dose of a pain medication – either through the nose or IV – from 56 minutes to 23 minutes. To ensure that there was no delay in placing the IV when intranasal fentanyl (2 doses) was used first, the team tracked the time to the second IV pain medication dose, which also decreased from 106 minutes to 83 minutes. There also was a reduction in the time it took for the physician to determine whether the patient would be admitted (from 163 minutes to 109 minutes) or discharged (from 271 minutes to 178 minutes). In addition, patients who were admitted were given patient-controlled analgesics (PCA) to control their pain, and the time to its initiation decreased from 216 minutes to 141 minutes.
The data also showed that while the proportion of discharged patients increased from 32 to 48 percent, there was no increase in patients returning to the emergency department within 24 hours of their initial visit nor was there an increased number of hospitalizations for patients who were admitted.
“By working collaboratively with caregivers across the emergency department to implement these changes, BMC has significantly improved the quality of care for BMC’s young patients with SCD during emergency situations,” said James Moses, MD, MPH, director of patient safety and quality for pediatrics at BMC and assistant professor of medicine at BUSM. “While future studies are necessary to determine if these results can be replicated at other hospitals, our data indicates that these initiatives could have a tremendous impact on care for kids with SCD across the country.”
This research was funded in part by the Health Resources and Services Administration’s Sickle Cell Disease Newborn Screening Program under notice of grant award number U38 MC22215-02-00.
About Boston Medical Center
Boston Medical Center is a private, not-for-profit, 496-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Committed to providing high-quality health care to all, the hospital offers a full spectrum of pediatric and adult care services including primary and family medicine and advanced specialty care with an emphasis on community-based care. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $118 million in sponsored research funding in fiscal year 2014. It is the 11th largest recipient of funding in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. It does business in Massachusetts as BMC HealthNet Plan and as Well Sense Health Plan in New Hampshire, serving more than 315,000 people, collectively. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet – 13 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.bmc.org.
Contact: Jenny Eriksen Leary, 617-638-6841, firstname.lastname@example.org